Aktiesnakken — Januar 2011
-
det gør de nok ikke hvis de ikke tror på Arzerra
-
der var ikke mange andre der blev nævnt
-
Jeg kan rigtigt godt lide det de gør, GSK. med forretningsmodellen
-
det er bestemt en mulighed. Men det er nok også blue sky for markedet er vel max 10bn?
-
hvis arzerra bliver 5bn. Så tjener genmab 5 milliarder i royalties
-
ahh ok
-
så er jeg mere med
-
5bn ligger nok fremme i 2016-17
-
Genmab er ikke dyr ihvertfald Pro
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind